Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Alison Handley, Eric Lloyd, Andrew Roberts & Bruce Barger. (2016) Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study. Clinical and Experimental Hypertension 38:2, pages 180-188.
Read now
Read now
Vivencio Barrios & Carlos Escobar. (2013)
Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?. Expert Opinion on Pharmacotherapy 14:16, pages 2249-2261.
Read now
Read now
Carlos Escobar & Vivencio Barrios. (2013) An evaluation of the latest evidence relating to renin–angiotensin system inhibitors. Expert Opinion on Drug Metabolism & Toxicology 9:7, pages 847-858.
Read now
Read now
Articles from other publishers (11)
Chaicharn Deerochanawong, Kuan-Cheng Chang, Yu Cho Woo, Wen-Ter Lai & Aurauma Chutinet. (2022) A Prospective Study of Azilsartan Medoxomil in the Treatment of Patients with Essential Hypertension and Type 2 Diabetes in Asia. International Journal of Hypertension 2022, pages 1-9.
Crossref
Crossref
Santosh Kumar Puttrevu, Rachumallu Ramakrishna, Manisha Bhateria, Moon Jain, Kashif Hanif & Rabi Sankar Bhatta. (2017) Pharmacokinetic-pharmacodynamic modeling of the antihypertensive interaction between azilsartan medoxomil and chlorthalidone in spontaneously hypertensive rats. Naunyn-Schmiedeberg's Archives of Pharmacology 390:5, pages 457-470.
Crossref
Crossref
A. A. Spasov, D. S. Yakovlev & A. A. Brigadirova. (2017) Angiotensin AT1 Receptors and Their Ligands (Review). Pharmaceutical Chemistry Journal 51:1, pages 1-8.
Crossref
Crossref
Anselm K. Gitt, Peter Bramlage, Sebastian A. Potthoff, Peter Baumgart, Felix Mahfoud, Hartmut Buhck, Martina Ehmen, Taoufik Ouarrak, Jochen Senges & Roland E. Schmieder. (2016) Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry. BMC Cardiovascular Disorders 16:1.
Crossref
Crossref
Roland E. Schmieder, Sebastian A. Potthoff, Peter Bramlage, Peter Baumgart, Felix Mahfoud, Hartmut Buhck, Taoufik Ouarrak, Martina Ehmen, Jochen Senges & Anselm K. Gitt. (2015) Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin-Converting Enzyme Inhibitors: The Prospective EARLY Registry. The Journal of Clinical Hypertension 17:12, pages 947-953.
Crossref
Crossref
Jie Li & Lutz Ackermann. (2015) Cobalt-Catalyzed CH Arylations with Weakly-Coordinating Amides and Tetrazoles: Expedient Route to Angiotensin-II-Receptor Blockers. Chemistry - A European Journal 21:15, pages 5718-5722.
Crossref
Crossref
Mark S. Kipnes, Alison Handley, Eric Lloyd, Bruce Barger & Andrew Roberts. (2015) Safety, Tolerability, and Efficacy of Azilsartan Medoxomil With or Without Chlorthalidone During and After 8 Months of Treatment for Hypertension. The Journal of Clinical Hypertension 17:3, pages 183-192.
Crossref
Crossref
Lutz Ackermann. (2015) Robust Ruthenium(II)-Catalyzed C–H Arylations: Carboxylate Assistance for the Efficient Synthesis of Angiotensin-II-Receptor Blockers. Organic Process Research & Development 19:1, pages 260-269.
Crossref
Crossref
Emelyne Diers, N.Y. Phani Kumar, Tom Mejuch, Ilan Marek & Lutz Ackermann. (2013) Carboxylate-assisted ruthenium(II)-catalyzed C–H arylations of 5-aryl tetrazoles: step-economical access to Valsartan. Tetrahedron 69:22, pages 4445-4453.
Crossref
Crossref
Uwe Fricke & Ulrich Schwabe. 2013. Arzneiverordnungs-Report 2013. Arzneiverordnungs-Report 2013
47
120
.
Michael Bader, Robson A Santos, Thomas Unger & U Muscha Steckelings. (2012) New therapeutic pathways in the RAS. Journal of the Renin-Angiotensin-Aldosterone System 13:4, pages 505-508.
Crossref
Crossref